uxawazebryauxwewdbceae

Latest

Jun 20, 2017
There is a tremendous, untapped market of undiagnosed patients for a variety of conditions, writes John Pagliuca. But how do you identify them when they are essentially hidden from view through conventional means?
Jun 20, 2017
Most challenges boil down to two simple categories: "complicated" and "complex". Knowing how to categorize each problem is key to solving it, writes Steve Figman.
Jun 16, 2017
Pharmaceutical Executive
Pharm Exec's 17th annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.
Jun 11, 2017
Jackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.
Jun 08, 2017
Pharmaceutical Executive
In the 21st Century Cures Act, Congress excluded from FDA regulation certain clinical decision support, or CDS, software.
May 12, 2017
The absence of pharma brands on social media creates a significant void of reputable healthcare information to aid patients, writes Dawn Lacallade.
May 12, 2017
Clinical trial data from completed trials are beginning to be shared through a variety of channels. While skeptics remain, there is evidence that this data can lead to practice-changing behavior in patient care.
May 08, 2017
The agency hopes to better use global resources and avoid duplicate inspections of foreign facilities.
May 04, 2017
Effectively addressing prior authorization challenges as part of a company’s core sales and marketing tactics can yield tangible and substantial benefits, writes Dan Rubin.
Apr 26, 2017
By Pharmaceutical Executive Editors
A new report from QuintilesIMS asks, it more advantageous to take a product to market by "Going It Alone" or by partnering with an established pharma company?
lorem ipsum